MTRAC issued two new Commissioning Support reviews in October 2013. The reviews cover perampanel and zonisamide.
The perampanel (Fycompa®) summary advises that this drug is not suitable for prescribing in primary care for adjunctive treatment of partial seizures in epilepsy. It is recommended that prescribing should occur in a tertiary care setting and notes that patients are likely to receive continued specialist supervision.
The zonisamide (Zonegran®) summary advises that this drug is suitable for restricted prescribing under defined conditions as monotherapy for partial seizures in epilepsy. It is recommended that the treatment is initiated and stabilised by a specialist after which maintenance therapy can be issued in primary care. It is expected that patients would continue to receive follow-up in secondary care.
Action: Clinicians should be aware of these reviews and use the recommendations to guide appropriate use of these medicines in current practice.
|« Drug Safety Update - October 2013||NICE Guidance - October 2013 »|